The point-of-care opioid testing market is anticipated to reach a valuation of US$ 450.9 million by 2023. The market is anticipated to grow at a 4.9% CAGR over the course of the forecast period, reaching US$ 725.1 million by 2033. The growing opioid epidemic, growing public awareness of drug abuse, and the demand for effective testing techniques have all contributed to the market’s notable growth in point-of-care opioid testing in recent years. The market is anticipated to keep growing as long as there is a need for quick and precise drug test solutions.
The demand for point-of-care opioid testing is expected to continue rising due to the ongoing opioid epidemic and the need for effective monitoring and intervention. Governments, healthcare providers, workplaces, and law enforcement agencies are increasingly recognizing the importance of rapid and accurate drug testing to address the crisis. This demand will be a significant driver for market growth.
Get a Sample Copy of the Report:
https://www.futuremarketinsights.com/reports/sample/rep-gb-17625
Advancements in testing technologies, including immunoassays, biosensors, molecular diagnostics, and digital health platforms, are enhancing the performance, sensitivity, specificity, and connectivity of point-of-care opioid testing devices. These technological innovations improve the accuracy, speed, and user experience of testing, driving market growth and adoption.
Point-of-care opioid testing is expanding beyond traditional healthcare settings, such as hospitals and clinics, into non-traditional settings like workplaces, home care, and telehealth. The convenience and accessibility of testing in these settings address the need for decentralized healthcare and patient-centric testing, creating new market opportunities.
Key Takeaways:
- The point-of-care opioid testing industry in the United States is predicted to reach US$ 227.4 million by 2033, increasing at a 4.2% CAGR.
- The point-of-care opioid testing industry in the United Kingdom is estimated to reach a market value of US$ 32.0 million, expanding at a CAGR of 4.3% by 2033.
- During the forecast period, the point-of-care opioid testing industry in China is expected to reach a market value of US$ 54.7 million, securing a 6.4% CAGR.
- The point-of-care opioid testing industry in Japan is predicted to reach US$ 39.9 million by 2033, increasing at a 6.2% CAGR.
- During the forecast period, the point-of-care opioid testing industry in South Korea is expected to reach a market value of US$ 45.4 million, securing a 6.0% CAGR.
- With a CAGR of 4.7% from 2023 to 2033, the test strips is expected to dominate the point-of-care opioid testing industry.
- With a CAGR of 5.2% from 2023 to 2033, the Multi-panel drug test kits is expected to dominate the point-of-care opioid testing industry.
- With a CAGR of 4.9% from 2023 to 2033, the Blood sample is expected to dominate the point-of-care opioid testing industry.
- With a CAGR of 5.4% from 2023 to 2033, the forensic laboratories is expected to dominate the point-of-care opioid testing industry.
Key Players:
- Avon Healthcare
- Triveni Traders Diagnostic Private Limited
- AdvaCare Pharma USA
- BTNX Inc.
- Phamatech
- ADC
- Worldwide Medical Corporation
- Accu-Stat Diagnostics, Inc
- ACON Laboratories, Inc.
- Alere
- Innovacon, Inc.
- Amedica Biotech, Inc
- Branan Medical Corporation
- Biosite Inc
- UCP Biosciences, Inc
- TransMed Company
- Vitrosens Biotechnology
- Abbot
- clarity diagnostics
- Alcotec Company Limited
Key Developments:
- In November 2022, Abbott receives three CES 2023 Innovation awards for advancements in health technology.
- In August 2019, Intoximeters and Abbott recently established a partnership to commercialise Abbott’s SoToxaTM Mobile Test System, a portable oral fluid roadside testing device that accurately and quickly identifies recent drug use.
Segmentation Analysis of the Point-of-care opioid testing Market
By Product:
- Strips
- Cassettes
- Drug Test Dip Cards
By Modality:
- Single-panel Drug Test Kits
- Multi-panel Drug Test Kits
By Sample:
- Saliva
- Blood
- Urine
- Others
By End User:
- Hospitals
- Diagnostics Laboratories
- Forensic Laboratories
- Home Care Settings
- Others
By Region:
- North America
- Latin America
- Europe
- East Asia
- South Asia
- Oceania
- The Middle East Africa
Unlock Tailored Insights: Customize Your Report for Maximum Impact:
https://www.futuremarketinsights.com/customization-available/rep-gb-17625
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube